Tarsus Pharmaceuticals Inc

NASDAQ: TARS
$52.22
-$0.85 (-1.6%)
Real Time Data Delayed 15 Min.

TARS Stock Chart and Intraday Price

TARS Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 15440 LAGUNA CANYON ROAD, IRVINE, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,264.10M USD
Shares Outstanding 34,211,200
Tarsus Pharmaceuticals is a pioneering biopharmaceutical company based in Irvine, California, dedicated to developing innovative treatments for eye care. Its flagship product, XDEMVY, targets the treatment of blepharitis from Demodex mites and meibomian gland disease. Beyond eye care, Tarsus is expanding its reach into dermatology and infectious disease prevention, with products like TP-04 for rosacea and TP-05 for Lyme disease prophylaxis and malaria reduction. Founded in 2016, Tarsus is committed to addressing unmet medical needs in various therapeutic areas.

TARS Articles

In late Monday morning trading, tech stocks are getting crushed, with the Invesco QQQ Trust (NASDAQ:QQQ) down 3.1%. Investors are second-guessing valuations of U.S.-listed tech stocks after the most...
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.